Loading...

Swedish Orphan Biovitrum AB (publ)

BIOVFPNK
Healthcare
Drug Manufacturers - Specialty & Generic
$29.79
$0.00(0.00%)

Swedish Orphan Biovitrum AB (publ) (BIOVF) Stock Overview

Explore Swedish Orphan Biovitrum AB (publ)’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 78.4/100

Key Financials

Market Cap10.3B
P/E Ratio24.59
EPS (TTM)$1.33
ROE0.10%
Fundamental Analysis

AI Price Forecasts

1 Week$30.13
1 Month$28.27
3 Months$33.30
1 Year Target$31.73

BIOVF Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Swedish Orphan Biovitrum AB (publ) (BIOVF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 55.53, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $31.73.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 24.59 and a market capitalization of 10.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;